Arsenal Biosciences, Inc.
3 clinical trials · Sponsor
◉ Watch Arsenal Biosciences, Inc.
| Record | Firm | Date |
|---|---|---|
| AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC) (NCT07285694) | Arsenal Biosciences, Inc. | 2026-01-09 |
| AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC) (NCT06245915) | Arsenal Biosciences, Inc. | 2024-02-26 |
| AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer (NCT05617755) | Arsenal Biosciences, Inc. | 2022-11-29 |
Track Arsenal Biosciences, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.